NO20081628L - Benzodiazepiner som HCV-inhibitorer - Google Patents

Benzodiazepiner som HCV-inhibitorer

Info

Publication number
NO20081628L
NO20081628L NO20081628A NO20081628A NO20081628L NO 20081628 L NO20081628 L NO 20081628L NO 20081628 A NO20081628 A NO 20081628A NO 20081628 A NO20081628 A NO 20081628A NO 20081628 L NO20081628 L NO 20081628L
Authority
NO
Norway
Prior art keywords
benzodiazepines
relates
present
hcv
compounds
Prior art date
Application number
NO20081628A
Other languages
English (en)
Norwegian (no)
Inventor
Frederic Marc Maurice Doublet
Jean-Francois Bonfanti
Origene Nyanguile
Pierre Jean-Marie Be Raboisson
Anne-Sophie Helene Ma Rebstock
Carlo Willy Maurice Boutton
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of NO20081628L publication Critical patent/NO20081628L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20081628A 2005-09-02 2008-04-02 Benzodiazepiner som HCV-inhibitorer NO20081628L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05108058 2005-09-02
EP05110606 2005-11-10
PCT/EP2006/065938 WO2007026024A2 (fr) 2005-09-02 2006-09-01 Benzodiazepines en tant qu'inhibiteurs du vhc

Publications (1)

Publication Number Publication Date
NO20081628L true NO20081628L (no) 2008-05-29

Family

ID=37719242

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081628A NO20081628L (no) 2005-09-02 2008-04-02 Benzodiazepiner som HCV-inhibitorer

Country Status (14)

Country Link
US (1) US20090221559A1 (fr)
EP (1) EP1937272A2 (fr)
JP (1) JP2009507004A (fr)
KR (1) KR20080040032A (fr)
AR (1) AR056193A1 (fr)
AU (1) AU2006286441A1 (fr)
BR (1) BRPI0615922A2 (fr)
CA (1) CA2620777A1 (fr)
IL (1) IL189626A0 (fr)
MX (1) MX2008003032A (fr)
NO (1) NO20081628L (fr)
RU (1) RU2008112661A (fr)
TW (1) TW200800225A (fr)
WO (1) WO2007026024A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008099021A1 (fr) * 2007-02-16 2008-08-21 Tibotec Pharmaceuticals Ltd. Dibenzodiazépinones utiles comme inhibiteurs du virus de l'hépatite c
WO2008099019A1 (fr) * 2007-02-16 2008-08-21 Tibotec Pharmaceuticals Ltd. 6-hydroxy-dibenzodiazépinones utiles comme inhibiteurs du virus de l'hépatite c
AU2008339917B2 (en) 2007-12-24 2013-02-07 Tibotec Pharmaceuticals Macrocyclic indoles as hepatitis C virus inhibitors
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
CN102984941B (zh) 2009-09-04 2016-08-17 密执安大学评议会 用于治疗白血病的组合物和方法
US9127010B2 (en) 2010-06-24 2015-09-08 Janssen Sciences Ireland Uc Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid
WO2013068592A1 (fr) * 2011-11-10 2013-05-16 Fondation Jerome Lejeune Inhibiteurs de la cystathionine bêta synthase utilisables en vue de la réduction de la surproduction neurotoxique de sulfure d'hydrogène endogène
CA2859985C (fr) 2011-12-21 2020-11-03 The Regents Of The University Of Colorado Composes anticancereux ciblant des gtpases ral et leurs procedes d'utilisation
CN103601721B (zh) * 2013-10-23 2016-04-27 江苏科技大学 3-呋喃基二苯并二氮卓-1-酮类系列衍生物及其制备方法和应用
EP3166609B1 (fr) 2014-07-10 2020-03-11 The Regents of The University of Colorado, A Body Corporate 6-amino-1,3-diméthyl-4-(4-(trifluorométhyl)phényl)-1,4-dihydropyrano [2,3-c]pyrazole-5-carbonitrile et composés similaires en tant qu'inhibiteurs de ral gtpase pour le traitement de métastases du cancer
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
WO2018175746A1 (fr) 2017-03-24 2018-09-27 Kura Oncology, Inc. Méthodes de traitement d'hémopathies malignes et du sarcome d'ewing
WO2018226976A1 (fr) 2017-06-08 2018-12-13 Kura Oncology, Inc. Procédés et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
EP3684361A4 (fr) 2017-09-20 2021-09-08 Kura Oncology, Inc. Inhibiteurs substitués de ménine-mll et méthodes d'utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
JP5127096B2 (ja) * 1999-04-30 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用
WO2004001058A2 (fr) * 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Composes modulateurs de facteurs de transcription et procedes d'utilisation
US20050123906A1 (en) * 2003-11-06 2005-06-09 Rana Tariq M. Protein modulation

Also Published As

Publication number Publication date
RU2008112661A (ru) 2009-10-10
EP1937272A2 (fr) 2008-07-02
CA2620777A1 (fr) 2007-03-08
US20090221559A1 (en) 2009-09-03
KR20080040032A (ko) 2008-05-07
MX2008003032A (es) 2008-03-24
AU2006286441A1 (en) 2007-03-08
JP2009507004A (ja) 2009-02-19
IL189626A0 (en) 2008-08-07
AR056193A1 (es) 2007-09-26
TW200800225A (en) 2008-01-01
WO2007026024A3 (fr) 2007-04-26
BRPI0615922A2 (pt) 2011-05-31
WO2007026024A2 (fr) 2007-03-08

Similar Documents

Publication Publication Date Title
NO20081628L (no) Benzodiazepiner som HCV-inhibitorer
NO20072235L (no) HCV-hemmende bicykliske pyrimidiner
NO20080540L (no) HCV-inhibitorer
MX2007014082A (es) Pirido[2,3-d]pirimidinas utiles como inhibidores del virus de la hepatitis c (hcv), y metodos para la preparacion de las mismas.
UY30759A1 (es) Compuestos quimicos
NO20091258L (no) Entantiomerisk rene fosfoindoler as HIV inhibitorer
NO20064584L (no) Tetrahydropyridoindolderivater
NO20090628L (no) Pyridizinon derivativater
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
NO20084256L (no) DPP IV inhibitorformuleringer
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
NO20073105L (no) Pyridazinonforbindelser
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
CL2008000959A1 (es) Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c.
MX348481B (es) Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas.
NO20082269L (no) Nye piperaziner som antimalariamidler
NO20060978L (no) Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering
WO2007084424A3 (fr) Traitement de l'abus de substances
BRPI0514736A (pt) inibidores do receptor sigma
CL2008003659A1 (es) Compuestos derivados de 6-(4-bencilpiperazin-1-il)pirimidin-4-ona, moduladores de la enzima estearoil-coa-desaturasa 1; procedimiento de preparacion; composicin farmaceutica; y uso en el tratamiento y profilaxis de la obesidad.
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
UA91848C2 (ru) Применение соединений диосметина в лечении и предотвращении тромботическим патологиям
CL2008003231A1 (es) Compuestos derivados de 1,3-dihidro-5-isobenzofurancarbonitrilo sustituido, inhibidores selectivos de la recaptacion de serotonina; composicion farmaceutica; procedimiento de preparacion; utiles en el tratamiento y/o prevencion de la eyaculacion prematura.
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application